Three years ago, BridgeBio Pharma was a research-stage company watching its revenue collapse in a single year, the casualty of a licensing deal unwinding and no approved product to replace it. Today, a single drug called Attruby is pulling in more revenue every quarter than the entire company earned across all of 2021. That reversal is real. What the market is still deciding is whether three more drugs can repeat it, and whether the cash lasts long enough to find out.
The quick read
Attruby, BridgeBio’s approved heart drug, more than doubled quarterly revenue year over year as of the 10-Q filed August 10, 2026. The company is still losing money every quarter, burning through cash at a pace that would have exhausted its pre-July reserves in roughly sixteen months. Three separate FDA decisions are now scheduled between November 2026 and May 2027. The math and the mood point in different directions: the filed cash runway assumes at least one approval is needed to sustain operations, while the current price-to-sales ratio historically has reflected expectations of multiple pipeline successes. Readers can weigh which scenario the evidence better supports.
What the filing changed
The June 30, 2026 quarterly report landed with a contrast that stops you cold: $243.7 million in revenue for the quarter, and a net loss of $152.2 million in the same three months. A company can run that way for a while, but not forever, and the filing makes the timeline concrete. Cash, equivalents, and marketable securities stood at $720.2 million at quarter’s end, while the company burned through a substantial sum in the first half of 2026 alone. At that pace, the pre-July cash pile covers about sixteen months.
The filing also captures a structural shift that happened the day after the period closed. On July 1, 2026, BridgeBio closed a $1 billion preferred equity financing led by Sixth Street, with KKR’s HealthCare Royalty participating. That pushed the available cushion to roughly $1.7 billion. Preferred equity is not free money: it sits above common shareholders in any claim on the company’s assets, meaning existing shareholders absorbed dilution in exchange for the runway. The company said explicitly the funds are earmarked for three potential upcoming product launches and continued pipeline work.
The drug doing the work
Attruby (acoramidis) treats a heart condition called ATTR-CM, where a protein misfolds and stiffens the heart muscle over time. The drug stabilizes that protein. It earned FDA approval in late 2024, and by the most recent quarter it was generating $222.4 million in a single quarter, according to the 10-Q. For context, the entire company booked $70 million in revenue across all of 2021. One drug now earns more than three times that in ninety days.
On August 31, 2026, BridgeBio announced a voluntary agreement with the U.S. government to expand Attruby access through state Medicaid programs under the GENEROUS Model. Broader access can lift volume; it can also compress the average price received per dose. The filing does not yet show how that trade-off resolves.
Three clocks ticking
The more consequential part of the filing, read alongside announcements through October 13, is the regulatory calendar now locked in. BBP-418, a treatment for a rare muscle disease called LGMD2I/R9, faces an FDA decision on November 27, 2026. Oral infigratinib, for children with a bone-growth condition called achondroplasia, received FDA Priority Review acceptance on October 6, 2026, with a decision due February 4, 2027. Encaleret, for a rare calcium disorder called ADH1, has a decision date of May 8, 2027, after the FDA accepted its application on July 22, 2026.
All three received Priority Review, which the FDA grants when a drug may offer a meaningful improvement over existing options. Priority Review shortens the standard review clock; it does not change the approval odds. The encaleret Phase 3 CALIBRATE results announced October 11, 2026 showed that nearly every treated patient experienced symptom improvements, compared with fewer than half on standard therapy, and that a large majority reached normal hormone levels after six months of treatment. The clinical data is striking. The regulatory outcome remains an open question that the filing cannot answer.
What the price assumes
The stock trades at $65.75 as of October 13, 2026, down more than a quarter from its fifty-two-week high. Our data puts the price-to-sales ratio at 25.3, against a decade median of 43.7 for this name, placing it at the 7th percentile of its own history on that measure. In plain terms: the market is paying about twenty-five times annual revenue for the business, which sounds expensive until you consider that for most of the past decade it paid even more. The mood has cooled relative to BridgeBio’s own past, even as the math, meaning what the filed revenue trend actually shows, has improved sharply.
William Blair, in a note cited by Investing.com on October 6, 2026, cited an additional $4 billion in de-risked peak sales opportunity from three upcoming product launches beyond Attruby. Barclays analyst Eliana Merle, on October 7, 2026, maintained an Overweight rating while trimming her valuation estimate only slightly, per GuruFocus. Those are their views, not ours. What the filed numbers confirm is that the revenue engine exists and is running. What they cannot confirm is whether three more engines start on schedule.
Reading the numbers
- $243.7 million, Q2 2026 revenue. What it is: total revenue for the three months ended June 30, 2026, per the 10-Q. What it means: revenue more than doubled from the same quarter a year earlier, almost entirely on Attruby sales. Everyday version: a shop that took in $100 last July took in $220 this July, with one product doing nearly all the lifting.
- $269 million, six-month cash burn. What it is: cash used in operations and investment in the first half of 2026, per the 10-Q. What it means: the company spends more than it earns, and the gap is still wide. Everyday version: a household earning $4,000 a month but spending $8,500 needs to keep dipping into savings, and the savings pile matters a great deal.
- ~$1.7 billion, post-July cash position. What it is: the $720.2 million on hand at June 30 plus the $1 billion preferred financing that closed July 1. What it means: at the H1 burn rate, this covers roughly three years of operations before any new revenue from the pipeline, giving the company time to absorb at least one regulatory outcome. Everyday version: the household above just received a large gift, buying time to find out whether the new job offers come through.
- P/S of 25.3 vs. decade median of 43.7. What it is: price-to-sales is the price tag per dollar of annual revenue; our data shows today’s ratio sits well below BridgeBio’s own historical norm. What it means: the market is currently assigning a lower revenue multiple than it has historically, even as revenue growth has accelerated. Everyday version: a restaurant that has historically changed hands at 44 times annual receipts is currently valued at 25 times, while customer traffic is at a record high, whether that gap reflects a bargain or a justified reassessment of risk is a question the valuation data alone cannot answer.
Sources
- 10-Q for quarter ended June 30, 2026 (SEC EDGAR)
- BridgeBio Q2 2026 earnings release
- BridgeBio $1 billion preferred equity announcement
- Business Insider: FDA accepts oral infigratinib NDA
- Minichart: oral infigratinib Priority Review, PDUFA February 4, 2027
- Seeking Alpha: encaleret CALIBRATE data and pipeline review
- GuruFocus: Barclays maintains Overweight, October 7, 2026
- Investing.com: William Blair reiterates Outperform, October 6, 2026
- BridgeBio FY2025 full-year results
